AVN 66.65 Decreased By ▼ -1.33 (-1.96%)
BOP 9.75 Decreased By ▼ -0.13 (-1.32%)
CHCC 129.95 Decreased By ▼ -3.55 (-2.66%)
DCL 11.20 Decreased By ▼ -0.35 (-3.03%)
DGKC 112.84 Decreased By ▼ -1.51 (-1.32%)
EFERT 60.75 Increased By ▲ 0.65 (1.08%)
EPCL 43.75 Decreased By ▼ -0.25 (-0.57%)
FCCL 21.05 Increased By ▲ 0.15 (0.72%)
FFL 17.45 Decreased By ▼ -0.20 (-1.13%)
HASCOL 20.96 Decreased By ▼ -0.21 (-0.99%)
HBL 131.75 Decreased By ▼ -1.25 (-0.94%)
HUBC 80.22 Decreased By ▼ -1.33 (-1.63%)
HUMNL 8.11 Decreased By ▼ -0.10 (-1.22%)
JSCL 30.70 Increased By ▲ 0.79 (2.64%)
KAPCO 26.49 Decreased By ▼ -0.41 (-1.52%)
KEL 4.16 Increased By ▲ 0.03 (0.73%)
LOTCHEM 12.50 Decreased By ▼ -0.40 (-3.1%)
MLCF 39.66 Decreased By ▼ -0.51 (-1.27%)
OGDC 104.33 Decreased By ▼ -3.92 (-3.62%)
PAEL 36.95 Decreased By ▼ -1.15 (-3.02%)
PIBTL 13.25 Decreased By ▼ -0.37 (-2.72%)
PIOC 98.50 Decreased By ▼ -0.50 (-0.51%)
POWER 9.38 Increased By ▲ 0.14 (1.52%)
PPL 93.11 Decreased By ▼ -2.17 (-2.28%)
PSO 201.50 Decreased By ▼ -0.50 (-0.25%)
SNGP 63.81 Decreased By ▼ -1.59 (-2.43%)
STPL 13.90 Decreased By ▼ -0.41 (-2.87%)
TRG 54.60 Decreased By ▼ -1.95 (-3.45%)
UNITY 18.10 Increased By ▲ 0.49 (2.78%)
WTL 1.19 Decreased By ▼ -0.03 (-2.46%)
BR100 4,346 Decreased By ▼ -8.53 (-0.2%)
BR30 22,083 Decreased By ▼ -141.56 (-0.64%)
KSE100 41,806 Decreased By ▼ -69.89 (-0.17%)
KSE30 17,659 Decreased By ▼ -15.57 (-0.09%)
COVID-19 TOTAL DAILY

WASHINGTON: The US has begun late stage clinical trials into a drug formulated to fight Covid-19, officials said Tuesday. The medicine is an antibody against the new coronavirus called LY-CoV555, which was identified in the blood sample of a recovered patient by Canada's Abcellera Biologics. It was then developed synthetically for mass production by US-based Lilly Research Laboratories in partnership with Abcellera.

The Phase 3 trial will initially enroll some 300 volunteers around the world who have been hospitalized with mild to moderate Covid-19 with fewer than 13 days of symptoms. Each will be assigned either the medicine, which will be injected intravenously, or a placebo.

Patients will also receive standard care for Covid-19, including the antiviral remdesivir. The new Phase 3 trial is being led by Jens Lundgren, of the University of Copenhagen and Rigshospitalet, and could expand to up to 1,000 people, including the more severely ill, if LY-CoV555 appears safe and effective after the fifth day. The trial's main goal is the patients' sustained recovery for 14 days after release from the hospital.